文献速递肾癌与肾肿瘤

肾髓质癌患者的临床特征、管理与结局:135例单中心回顾性分析

Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.
PubMed 文献 · Eur Urol Oncol · 2024-07-15

该单中心回顾性分析纳入2003年1月至2023年12月在MD安德森癌症中心治疗的135例肾髓质癌(RMC)患者,中位随访54.9个月。多数(78%)初诊即为转移性疾病,血尿是最常见症状(60%),生存结局随诊断年份改善(校正风险比0.70,95%CI 0.53-0.92,p=0.01)。

要点

  • RMC常以血尿起病,易转移至腹膜后淋巴结。
  • 生存结局随诊断年份改善,校正风险比0.70。
  • RCCU-MP极罕见,中位总生存19.5个月。

核心结论

  • RMC常表现为血尿且极易转移至腹膜后淋巴结,当代管理下生存结局正在改善;RCCU-MP极罕见且侵袭性可能略低。

研究设计与样本

  • 单中心回顾性分析,纳入2003年1月至2023年12月在MD安德森癌症中心治疗的全部135例RMC患者,采用多变量Cox回归按诊断时期估计总生存。

主要发现

  • 135例患者中位随访54.9个月,仅9例无镰状血红蛋白病而归为髓样表型的未分类肾细胞癌(RCCU-MP)。
  • 78%的患者初诊即为转移性疾病,主要转移至腹膜后淋巴结(81.7%)。
  • 合并镰状血红蛋白病的RMC患者中最常见首发症状为血尿(60%)。
  • 生存结局随诊断年份改善(校正风险比0.70,95%CI 0.53-0.92,p=0.01)。
  • RCCU-MP患者年龄稍大,自诊断起中位总生存19.5个月,无右肾好发或男性优势,以白人为主(89%)。

局限性

  • 研究为单中心开展的回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: SMARCB1-deficient renal medullary carcinoma (RMC) is a rare kidney cancer associated with sickle cell hemoglobinopathies with poor outcomes described only in case reports and small series. We report disease and management characteristics as well as contemporary survival outcomes in a large cohort of patients with RMC. METHODS: Data were extracted retrospectively from all patients with RMC treated at MD Anderson Cancer Center between January 2003 and December 2023. Multivariable Cox regression was used to estimate overall survival (OS) by diagnosis period. KEY FINDINGS AND LIMITATIONS: Among 135 patients (median follow-up of 54.9 mo), only nine did not harbor a sickle hemoglobinopathy and were categorized as having renal cell carcinoma, unclassified with medullary phenotype (RCCU-MP). Most patients (78%) presented with metastatic disease, predominantly to the retroperitoneal lymph nodes (81.7%), and hematuria was the most frequent presenting symptom (60%) in RMC associated with sickle hemoglobinopathy. Survival outcomes improved by diagnosis year (adjusted hazard ratio 0.70, 95% confidence interval 0.53-0.92, p = 0.01). RCCU-MP occurred in slightly older patients with median OS of 19.5 mo from diagnosis, did not show a predilection to the right kidney or male predominance, and afflicted mainly Caucasians (89%). The study is limited by its retrospective nature conducted at one center. CONCLUSIONS AND CLINICAL IMPLICATIONS: RMC frequently presents with hematuria and is highly likely to spread to the retroperitoneal lymph nodes. Survival outcomes are improving with contemporary management. RCCU-MP is very rare and may be slightly less aggressive. PATIENT SUMMARY: Renal medullary carcinoma (RMC) is a rare and aggressive subtype of kidney cancer afflicting primarily young men and women of African descent. There exist limited data regarding patient demographics and disease characteristics. We reported our institution's experience in treating patients with RMC. The first symptom most patients with RMC reported was blood in the urine, and the most common places where the cancer spread were the lymph nodes around the kidney. Patients with RMC are living longer with contemporary treatments.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lebenthal JM, Kontoyiannis PD, Hahn AW, et al. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients. Eur Urol Oncol. 2024. PMID: 39013742. doi:10.1016/j.euo.2024.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。